Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 2,409 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Invasive Procedure Clear all

Conditions: Spinal Cord Injuries
Interventions: CES at rest, CES plus active hand or wrist movements; Device
Lead sponsor: Bronx VA Medical Center; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Mitochondrial Myopathies, Mitochondrial Diseases
Interventions: Nanosensor; Device
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Uterine Cervix Cancer
Interventions: Nelfinavir, Cisplatin; Drug · Biological
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Bladder Cancer, NMIBC, Non-Muscle Invasive Bladder Cancer, Urothelial Carcinoma Recurrent
Interventions: Pemigatinib; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Syracuse, New York + 3 more

Conditions: Breast Neoplasms
Interventions: Exemestane, Calcium carbonate, Vitamin D; Drug · Dietary Supplement
Lead sponsor: Georgetown University; Other
Eligibility: Female only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Ischemic Stroke
Interventions: Guardian System; Device
Lead sponsor: TurnCare Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Jose, California

Conditions: Breast Cancer, Triple Negative Breast Cancer, HER2+ Breast Cancer, Hormone Receptor Negative Breast Cancer, Metastatic Breast Cancer
Interventions: Brachyury-TRICOM, Entinostat, M7824, Ado-trastuzumab emtansine; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Carcinoma, Colon Carcinoma, Invasive Carcinoma, Kidney Carcinoma, Liver Carcinoma, Malignant Solid Neoplasm, Multiple Myeloma, Prostate Carcinoma
Interventions: Biospecimen Collection, Laboratory Biomarker Analysis; Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 2,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Acute Respiratory Distress Syndrome, Acute Lung Injury, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS), Traumatic Brain Injury
Interventions: nVNS, SOC; Device · Other
Lead sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute); Other
Eligibility: 12 Years to 80 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Candidemia
Interventions: Not listed
Lead sponsor: T2 Biosystems; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 5
States / cities: Birmingham, Alabama • San Francisco, California • Lexington, Kentucky + 2 more

Conditions: Stroke, Aphasia
Interventions: transcranial direct current stimulation; Device
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Subcutaneous Fat
Interventions: 1064nm Laser, 940nm Laser; Device
Lead sponsor: Cynosure, Inc.; Industry
Eligibility: 20 Years to 55 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Staten Island, New York

Conditions: Invasive Breast Cancer
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 99 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 2
States / cities: Scottsdale, Arizona • Rochester, Minnesota

Conditions: Congestive Heart Failure
Interventions: CT angiography; Procedure
Lead sponsor: VA Connecticut Healthcare System; Federal
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Aspergillosis, Candidiasis, Fungal Diseases, Mycoses
Interventions: Voriconazole; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non-Muscle Invasive Bladder Neoplasms
Interventions: TAR-210, Mitomycin C, Gemcitabine; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 27
States / cities: Sun City, Arizona • Los Angeles, California • Lakewood, Colorado + 23 more

Conditions: Intracranial Hypertension, Elevated ICP (Intracranial Pressure)
Interventions: No Interventions; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 89 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Bladder Cancer, Non-muscle Invasive Bladder Cancer
Interventions: Not listed
Lead sponsor: Photocure; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: Tampa, Florida • Iowa City, Iowa • Ann Arbor, Michigan + 2 more

Conditions: Bladder Cancer
Interventions: Bacillus Calmette-Guerin (BCG); Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 99 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Pain, Postoperative
Interventions: Gabapentin, Acetaminophen, Celecoxib; Drug
Lead sponsor: Christiana Care Health Services; Other
Eligibility: 18 Years and older · Female only
Enrollment: 137 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma
Interventions: BCG Solution, BCG Tokyo-172 Strain Solution, BCG Tokyo-172 Strain Vaccine, Laboratory Biomarker Analysis; Biological · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 174
States / cities: Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 111 more

Conditions: Invasive Meningococcal Disease
Interventions: Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV., Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV., Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine., Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 10 Years to 25 Years
Enrollment: 484 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 8
States / cities: Birmingham, Alabama • Madera, California • Paramount, California + 5 more

Conditions: Breast Cancer, Metastatic Breast Carcinoma, Invasive Breast Carcinoma
Interventions: Carboplatin, Cyclophosphamide, Thiotepa, Stem Cell Transplant; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Renal Transplant Rejection
Interventions: Feraheme, MRI-GE Healthcare 3 Tesla magnet; Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 8 Years to 40 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Stanford, California

Search by objective public record fields.

Non-invasive Cervical Electrical Stimulation for SCI

Validation of Oxygen Nanosensor in Mitochondrial Myopathy

A Study of Nelfinavir Added to Cisplatin Chemotherapy Concurrent With Pelvic Radiation for Locally Advanced Cervical Cancer (II-IVA)

A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer

Study of the Guardian System on Motor Recovery and Impact on Length of Stay in Ischemic Stroke Patients

BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)

Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery

Non-invasive Vagal Neurostimulation (nVNS) for Traumatic Brain Injury (TBI)-Induced Acute Respiratory Distress

Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT)

Evaluating Anodal tDCS Preceding Aphasia Therapy

Evaluation of the Safety and Precursors of Efficacy

Breast Cancer Genome Guided Therapy Study (BEAUTY)

Study of Coronary Artery Disease by Two Types of Angiography

Voriconazole to Prevent Systemic Fungal Infections in Children

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

A Continuous, Non-Invasive, Real-time Method for Estimating and Predicting Intracranial Hypertension

Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy

PRIME: Pilot Study Evaluating Percutaneous Vaccination of BCG for Bladder Cancer

Single Dose Preoperative Gabapentin Use in Minimally Invasive Hysterectomy for Acute Pain Management

S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer

Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults

Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer

Imaging Kidney Transplant Rejection Using Ferumoxytol-Enhanced Magnetic Resonance